They started with genes instead of symptoms, and let the data guide them.
In the autumn of 2020, researchers at the National Institutes of Health gave a name to a silent killer that had long eluded medicine's gaze — VEXAS syndrome, a genetic disease born from a single mutation on the X chromosome, striking men with particular cruelty precisely because they carry no second copy to soften the blow. The discovery emerged not from the usual path of symptom to cause, but from its reversal: scientists began with the genome and let it speak for itself, uncovering an explanation for thousands of men who had suffered without diagnosis. With a mortality rate of forty percent, the finding is both a reckoning with how much illness hides in plain sight and a fragile first light for those still searching for answers.
- Men were dying from a disease that had no name — their blood clotting, their cartilage inflaming, their lungs deteriorating — while specialists passed them from clinic to clinic without resolution.
- The 40% mortality rate among known patients gave the discovery an immediate and sobering weight, transforming a scientific announcement into a human emergency.
- NIH researchers broke from convention, reversing the diagnostic process entirely — starting with 2,500 undiagnosed patients' genetic sequences rather than their symptoms, and letting the data lead the way.
- The culprit was a mutation in the UBA1 gene on the X chromosome, a location that left men genetically unprotected while women's second X chromosome likely shielded them from the disease's full force.
- Publication in the New England Journal of Medicine signaled to the broader medical community that a new diagnostic category had arrived, offering patients in limbo both a name for their suffering and a target for future treatment.
In the fall of 2020, the National Institutes of Health announced the identification of a rare and lethal genetic disease that had been quietly killing men for years without explanation. Called VEXAS syndrome — its name drawn from the cellular and genetic features that define it — the condition stems from a mutation in a single gene, UBA1, located on the X chromosome. Four out of every ten people known to have the disease had already died from it.
The symptoms were wide-ranging and severe: blood clots, inflamed cartilage, lung abnormalities, recurring fevers, and unusual vacuoles — hollow cavity-like structures — visible inside myeloid cells under a microscope. Patients had spent years cycling through specialists, their illnesses resisting every attempt at diagnosis.
The disease's near-exclusive appearance in men came down to genetic arithmetic. Men carry only one X chromosome, leaving a mutation on it with no backup. Women, carrying two, likely benefit from a compensating copy — a protective buffer that kept the disease largely invisible to medicine for so long.
The NIH team reached their discovery by inverting the traditional method. Rather than grouping patients by shared symptoms and searching for a genetic cause, they began with roughly 2,500 undiagnosed patients in their database and scanned their genomes for variations that might explain their suffering. Lead researcher Dr. David Beck reasoned that if conventional diagnostics had failed these patients, perhaps the genome itself could offer a different entry point.
The findings, published in the New England Journal of Medicine, were recognized as a meaningful advance. For patients who had lived for years in diagnostic limbo, VEXAS finally gave their suffering a name, a mechanism, and — for the first time — a direction for treatment.
In the fall of 2020, researchers at the National Institutes of Health announced they had identified a rare and lethal genetic disease that had been killing men without anyone understanding why. The condition, known as VEXAS syndrome—a name derived from the cellular and genetic features that define it—stems from a mutation in a single gene called UBA1, located on the X chromosome. The discovery mattered because it offered an explanation for a cluster of patients whose inflammatory illnesses had resisted diagnosis, and because it carried a grim statistic: four out of every ten people known to have the disease had died from it.
The symptoms were varied and severe. Patients experienced blood clots forming in their veins. Their cartilage became inflamed. Their lungs developed abnormalities. They ran recurring fevers. Under a microscope, their myeloid cells—a type of white blood cell critical to immune function—contained unusual cavity-like structures called vacuoles, which gave the disease part of its name. These manifestations had sent patients through years of medical evaluation without resolution, visiting specialists who could not piece together what was happening inside their bodies.
What made VEXAS appear almost exclusively in men was the nature of its genetic inheritance. Men carry a single X chromosome, inherited from their mothers. Women carry two. When a mutation appears on the X chromosome in a man, there is no second copy to compensate, no backup. The researchers theorized that women's second X chromosome likely provided a protective buffer—even if one carried the mutation, the other could compensate. This genetic arithmetic explained why the disease had remained hidden for so long: it was not affecting women in ways that would trigger widespread recognition.
The NIH team arrived at their discovery through an unconventional approach. Rather than starting with patients who shared similar symptoms and then searching their genomes for explanations, they reversed the process. They took roughly 2,500 patients in the NIH database—people whose inflammatory conditions had never been diagnosed despite extensive medical workup—and systematically searched their genetic sequences for variations that might account for their illnesses. Dr. David Beck, a clinical fellow at the National Human Genome Research Institute and the lead author of the study, explained the reasoning: the clinic was full of patients with undiagnosed inflammatory diseases, and traditional diagnostic methods had failed them. So the team asked a different question: what if they started with genes instead of symptoms, and let the genetic data guide them toward the disease?
The answer was VEXAS. The researchers published their findings in the New England Journal of Medicine, and the medical community recognized the discovery as significant. Identifying a previously unknown disease in a population of patients who had been suffering in diagnostic limbo offered hope. Understanding the genetic mechanism opened a pathway toward developing treatments. The 40 percent mortality rate underscored the urgency. For the men and their families who had been living with undiagnosed illness, the discovery meant that their symptoms finally had a name, their condition had a cause, and researchers now had a target for intervention.
Notable Quotes
Instead of starting with symptoms first, they started with a list of genes, then studied the genomes of undiagnosed individuals to see where it takes us.— Dr. David Beck, National Human Genome Research Institute
The Hearth Conversation Another angle on the story
Why did it take so long to find this disease if it's been killing men all along?
Because it's rare, and because the symptoms look like other things—blood clots, inflammation, lung problems. Doctors would treat each symptom separately without seeing the pattern underneath. The men were scattered across different clinics, different specialists.
So the researchers essentially flipped the diagnostic playbook.
Exactly. Instead of waiting for patients to come in with a recognizable cluster of symptoms, they went looking through genetic data from people who'd already stumped everyone. They asked: what do these undiagnosed patients have in common at the DNA level?
And they found a mutation in the UBA1 gene.
On the X chromosome, yes. Which immediately explained why it was hitting men so hard. One X chromosome means no redundancy, no backup copy if something goes wrong.
Why hasn't this been discovered before?
Partly because it's rare. Partly because the symptoms are scattered—you don't see a clear syndrome until you look at the genetic level. And partly because the methodology was new. Most disease discovery starts with symptoms. This time, they started with genes.
What happens now?
Now researchers have a target. They know what's broken at the molecular level. That's the foundation for developing therapies. For the men who've been sick and undiagnosed, it's finally an answer.